Novartis to buy remaining Chiron shares in $5.1 billion deal

Share this article:
Novartis said it is buying the 58 percent of biopharmaceuticals company Chiron that it doesn't already own for $5.1 billion.
Some analysts perceive the move some as a prelude to more takeovers in the vaccines area amid growing concern over the spread of new diseases, including avian flu.
"Our plan is to turn around the Chiron vaccines business, which will require investments in R&D and manufacturing to increase quality and capacity, so that we can better meet customer demand and address public health needs," said Daniel Vasella, Novartis' chief executive. "Together with the dynamically growing diagnostics business, vaccines will form a new division, while biopharmaceuticals will be integrated into the existing pharmaceuticals business of Novartis,"
Chiron currently ranks fifth in the vaccines business with annual vaccine sales of $510 million. It is competing against rivals including GlaxoSmithKline, Sanofi-Pasteur, Merck and Wyeth.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Star Group merges with Vox Medica, Calcium NYC

Star Group merges with Vox Medica, Calcium NYC

The newly formed group will be known as Calcium with Steve Michaelson, formerly of Rosetta Wishbone, at the helm.

Survey finds pay doesn't make doctors happy

Survey finds pay doesn't make doctors happy

Medscape's survey of over 24,000 physicians found that a paycheck is not necessarily linked to a physician's professional satisfaction.

CDC sees declines in some diabetes complications

CDC sees declines in some diabetes complications

Centers for Disease Control data shows that diabetes complications including heart attack and amputation fell in the twenty years between 1990 and 2010. The bad news: the number of diagnosed ...